Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals PLC has announced the repurchase of 499,999 ordinary shares on June 1, 2026, at a volume-weighted average price of 1448.2312 pence, and a further 12,246 shares on June 3, 2026, at an average price of 1424.5716 pence, as part of its $250 million share buyback program. These repurchases, conducted through J.P. Morgan Securities plc, are intended to be cancelled, and following these transactions, Hikma will have 213,794,638 ordinary shares in issue.

Disclaimer*

UK 100

Latest directors dealings